$REPL News
Last published 2w ago
- 2w agoREPLReplimune's Second Quarter Fiscal 2027 Earnings Conference Call - REPLIMUNE GROUP INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Rapid Immune's second quarter fiscal 2027 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-
- 2w agoREPLReplimune Group, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoREPLReplimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate UpdateGlobeNewswireTUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE
- 2w agoREPLReplimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026GlobeNewswireWOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it
- 2mo agoREPLReplimune to Present at the Cantor Global Healthcare Conference 2026GlobeNewswireWOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that
- 2mo agoREPLHHS plans new FDA deputy commissioner roles for technology and drugs, sources sayCNBCHHS plans to name two deputy commissioners for technology and drugs, said two sources familiar with the matter.
- 2mo agoREPLReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant
- 2mo agoREPLThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLPR NewswireThe Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL...
- 2mo agoREPLReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate UpdateGlobeNewswireTUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to
- 3mo agoREPLSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLPR NewswireReplimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study
- 3mo agoREPLReplimune Announces Pricing of $150 Million Underwritten OfferingGlobeNewswireBOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL) ("Replimune"), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today
- 3mo agoREPLREPLIMUNE TUDRIQEV FDA ACCELERATED APPROVAL INVESTOR CALL - REPLIMUNE GROUP INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the TutraKev FDA Accelerated Approval Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answ
- 3mo agoREPLReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based RegimenGlobeNewswireBroad label to address high unmet need in advanced melanoma Replimune will host conference call on August 6, 2026 at 4:30 p.m. ET. WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc.
- 3mo agoMSMREPLFDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced MelanomaFDA Press ReleasesThe U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma. Tudriqev is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a progr ...
- 3mo agoREPLReplimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced MelanomaGlobeNewswireWOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome
- 4mo agoREPLReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateGlobeNewswireWOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial
- 4mo agoREPLReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced MelanomaGlobeNewswireWOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S.
- 4mo agoQUREREPLUniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agencyCNBCThe announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.
- 5mo agoREPLReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingGlobeNewswireWOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final
- 5mo agoREPLReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingGlobeNewswireWOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark
- 5mo agoREPLReplimune to resubmit twice-rejected drug for approval after FDA shakeupCNBCReplimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
- 5mo agoREPLReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAGlobeNewswireWOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following
- 6mo agoREPLFDA commissioner defends agency's drug approval decisions after wave of backlashCNBCU.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.
- 6mo agoREPLReplimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireWOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple
- 7mo agoREPLReplimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswireWOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the
- 8mo agoCMPXMRKSGENPFE+8Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightPR NewswireThe biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing...
- 8mo agoREPLReplimune to Present at Two Upcoming Investor ConferencesGlobeNewswireWOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members
- 9mo agoREPLReplimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial
- 10mo agoREPLReplimune to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members
- 1y agoREPLReplimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)GlobeNewswireWOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker
- 1y agoREPLReplimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireWOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial
- 1y agoREPLReplimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced MelanomaGlobeNewswireWOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S.
- 1y agoREPLReplimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025GlobeNewswireWOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a
- 1y agoREPLSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoREPLBREAKING: Replimune Shares Drop Over 40%; Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud LawsuitGlobeNewswireBOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (NASDAQ:REPL) and certain of its executives. Investors who
- 1y agoREPLReplimune Provides Update Following Type A Meeting with FDAGlobeNewswireWOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the
- 1y agoREPLINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimunePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune" or the...
- 1y agoREPLINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimunePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune" or the...
- 1y agoREPLReplimune Announces Type A Meeting Scheduled with FDAGlobeNewswireWOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A
- 1y agoREPLSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoREPLReplimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPLPR NewswireThe Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL...
- 1y agoREPLREPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoREPLThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPLGlobeNewswireNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ:REPL). Shareholders who purchased shares of REPL during the class period
- 1y agoREPLReplimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – REPLGlobeNewswireNEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ:REPL). Shareholders who purchased shares of REPL during the class period
- 1y agoREPLReplimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireWOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial
- 1y agoREPLREPL DEADLINE: Replimune Group Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud LawsuitGlobeNewswireBOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (NASDAQ:REPL) and certain of its executives. Investors who
- 1y agoREPLSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoCNCFLYWREPLSOCImportant Notice to Long-Term Shareholders of Centene Corporation (NYSE: CNC); Flywire Corporation (NASDAQ: FLYW); Replimune Group, Inc. (NASDAQ: REPL); and Sable Offshore Corporation (NYSE: SOC): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Centene Corporation (NYSE:CNC): Grabar Law Office is investigating claims on behalf of shareholders of Centene Corporation (NYSE:CNC). The investigation concerns
- 1y agoDVFLYWREPLSOCImportant Notice to Short and Long-Term Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); Flywire Corporation (NASDAQ: FLYW); Replimune Group, Inc. (NASDAQ: REPL); and Sable Offshore Corporation (NYSE: SOC): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): Grabar Law Office is investigating whether certain officers and directors of DoubleVerify Holdings, Inc. (NYSE:DV)
- 1y agoANROLAZRREPLRXSTImportant Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 27, 2025 (GLOBE NEWSWIRE) -- Alto Neuroscience, Inc. (NYSE:ANRO): Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. (NYSE:ANRO). The investigation